ImmunityBio, Inc.
IBRX
$7.82
-$0.24-2.98%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 14.73% | 15.40% | |||
| Total Other Revenue | 1,356.41% | 200.00% | |||
| Total Revenue | 15.91% | 15.47% | |||
| Cost of Revenue | 25.21% | -37.70% | |||
| Gross Profit | 15.86% | 16.00% | |||
| SG&A Expenses | 13.22% | 29.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.93% | 10.71% | |||
| Operating Income | 11.60% | -7.90% | |||
| Income Before Tax | 63.59% | -919.10% | |||
| Income Tax Expenses | -- | 106.67% | |||
| Earnings from Continuing Operations | 63.59% | -921.33% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -20.00% | 7.14% | |||
| Net Income | 63.59% | -921.54% | |||
| EBIT | 11.60% | -7.90% | |||
| EBITDA | 12.42% | -7.38% | |||
| EPS Basic | 64.39% | -884.35% | |||
| Normalized Basic EPS | 63.98% | -870.92% | |||
| EPS Diluted | 64.39% | -871.92% | |||
| Normalized Diluted EPS | 63.98% | -870.92% | |||
| Average Basic Shares Outstanding | 2.26% | 3.76% | |||
| Average Diluted Shares Outstanding | 2.26% | 3.76% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||